More news – Page 13
-
News
AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment
The move is part of biopharma's $50 billion pledge to US medicines manufacturing and R&D.
-
News
Biovectra teams up with Revolution Biomanufacturing in mRNA
The companies’ partnership covers messenger RNA design and production services.
-
News
First biosimilar version of J&J’s Simponi approved in Europe
Authorisation of the biosimilar Gobivaz provides a substitute biologic medicine to Simponi for individuals with immune-mediated diseases.
-
NewsMedicines manufacturing in the UK to receive £54m sustainability boost
R&D projects supported by the Centre for Process Innovation (CPI) aim to shape a sustainable, resilient and competitive future for pharma manufacturing.
-
NewsInsmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment
Oral small molecule treatment Brinsupri (brensocatib) could become a new standard of care for patients with the progressive lung disease.
-
NewsModerna strengthens US mRNA manufacturing capabilities with over $140m investment
The expansion places the pharma company’s full manufacturing loop in the US under one roof.
-
News
Internationally-compliant framework backs rabbit pyrogen test alternative
The approach aims to support broader FDA acceptance of the monocyte activation test (MAT) as a replacement, animal-free pyrogen test.
-
News
Johnson & Johnson targets oncology portfolio with $3bn Halda acquisition
Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.
-
NewsPharmaLab previews new conference tracks ahead of 2025 Düsseldorf event
The pharmaceutical laboratory meeting adds sessions on AI in labs, and quality in biologics, mRNA and analytics.
-
NewsItalian non-profit set for European gene therapy first in Wiskott-Aldrich syndrome
Fondazione Telethon’s Waskyra (etuvetidigene autotemcel) has been recommended for approval by the CHMP as a treatment for the rare disease.
-
NewsFDA hits Sarepta with liver warning labelling for its DMD drug Elevidys
As well as the new safety warnings for the Duchenne muscular dystrophy gene therapy, the biopharma company also faced a new, more restrictive licence for the treatment.
-
News
MHRA approves Leqembi IV maintenance as additional Alzheimer’s option
Decision provides UK Alzheimer’s patients with an alternative administration method for Eisai and Biogen’s antibody drug.
-
NewsGenetically engineered iPSCs see clinical-scale platelet manufacturing potential
By utilising patient-derived instead of donor-derived platelets, the method could offer a safer approach to platelet transfusions.
-
NewsCRDMO BioDuro appoints Yaohui Ji as global president for CMC
He joins from contract development and manufacturing organisation Porton Pharma Solutions.
-
NewsPharma's sustainability push continues as Merck signs renewable energy deal
The German pharma company’s agreement for its South Korea sites is the latest green initiative to be unveiled by the industry.
-
NewsFDA names Dr Richard Pazdur to replace George Tidmarsh as CDER Director
The FDA-veteran and oncology specialist will lead the US drug agency’s work ensuring the safety and efficacy of medicines.
-
NewsRoche’s fenebrutinib shows best-in-disease potential in multiple sclerosis
Phase III data suggest the drug could be the first high-efficacy, oral therapy for relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis.
-
News
Novartis opens third US radioligand manufacturing facility
California site adds to the Swiss pharma company’s operations in Florida and Texas.
-
News
Pfizer’s Metsera hunger sees it beat Novo Nordisk’s obesity biopharma offer
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
-
NewsAstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera
After Wegovy and Zepbound's success, competition for the next potential weight loss blockbuster heats up.